HER3-Targeted Drug Active in Advanced/Metastatic Breast Cancer
An antibody-drug conjugate (ADC) targeting HER3 produced objective responses in as many as 43% of patients with advanced breast cancer, a prospective clinical trial showed. Responses to patritumab deruxtecan (HER3-DXd) occurred in the three major types of breast cancer, ranging from 22.6% in triple-negative breast cancer (TNBC) to 30.1% in hormone receptor (HR)-positive/HER2-negative breast cancer […]
Antibody-Drug Conjugates Take Breast Cancer Field by Storm
Antibody-drug conjugates (ADCs) have taken the field of breast cancer by storm and appear poised to expand their reach into earlier lines of therapy and early-stage disease, a breast cancer specialist said here. ADCs offer an “exciting and effective drug delivery system” for multiple subtypes of metastatic breast cancer, and ongoing clinical trials are exploring […]